Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.50 |
| ▸ | MAP2K4 | P45985 | 3/20 | 0.50 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.50 |
| ▸ | MAPK6 | Q16659 | 3/20 | 0.50 |
| ▸ | MAPKAPK3 | Q16644 | 2/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.43 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.43 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 2/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | GYS1 | P13807 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1407266 | 0.86 | SMN1; SMN2 (0.50) | MAP2K4KIF11GYS1KDM4ESMN1; SMN2 | |
| SCHEMBL1407075 | 0.86 | ALDH1A1 (0.49) | ESR1MAP2K4FGFR1KIF11KDM4E | |
| SCHEMBL4032567 | 0.84 | KDM4E (0.40) | ESR1MAPK1MAP2K4MAPKAPK2MAPK6 | |
| SCHEMBL1407136 | 0.81 | MEN1 (0.44) | MEN1KMT2AMAPT | |
| SCHEMBL4032541 | 0.80 | PDPK1 (0.47) | ESR1MAPK1MAP2K4MAPKAPK2MAPK6 | |
| SCHEMBL20674188 | 0.79 | KIF11 (0.46) | ESR1KIF11KDM4ESMN1; SMN2MEN1 | |
| SCHEMBL4028606 | 0.78 | MAPK1 (0.62) | ESR1MAPK1MAP2K4MAPKAPK2MAPK6 | |
| SCHEMBL4025987 | 0.76 | CHEK1 (0.54) | ESR1MAPK1MAP2K4MAPKAPK2MAPK6 | |
| SCHEMBL4493386 | 0.76 | CTNNB1 (0.40) | ESR1KIF11ESR2KDM4ESMN1; SMN2 | |
| SCHEMBL2661233 | 0.74 | CHEK1 (0.55) | PDPK1FGFR1KIF11KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542976-B1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | WYETH CORP (US) | 2009-02-04 | — | — | EP | disclosed |
| CN-101054364-A | Substituted 4-(indazol-3-yl)phenols as estrogen receptor (ER) ligands and their use in the treatmentof inflammarory diseases | WYETH CORP (US) | 2007-10-17 | — | — | CN | disclosed |
| US-20070225349-A1 | Substituted 4-(Indazol-3-yl)phenols | WYETH (US) | 2007-09-27 | — | — | US | disclosed |
| US-7241791-B2 | Substituted 4-(indazol-3-yl)phenols | WYETH (US) | 2007-07-10 | — | — | US | disclosed |
| CN-1321984-C | Substituted 4- (indazol-3-yl) phenols as Estrogen Receptor (ER) ligands and their use in the treatment of inflammation | WYETH CORP (US) | 2007-06-20 | — | — | CN | disclosed |
| CN-1692102-A | Substituted 4- (indazol-3-yl) phenols as Estrogen Receptor (ER) ligands and their use in the treatment of inflammation | WYETH CORP (US) | 2005-11-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225349-A1 | Substituted 4-(Indazol-3-yl)phenols | INSR, TNNI3, INSRR | ESR1 1028/4885MAPK1 857/4885MAP2K4 793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.